News

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.
Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris ...
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Ladenburg, Germany, 24 April 2025 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures ...
Seeking Alpha4d
REGN Regeneron Pharmaceuticals, Inc.
Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye ...
Seeking Alpha4d
GNMSF Genmab A/S
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak ...
Le Lézard5d
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce an expansion of the Fields of Use in the current License Agreement to include ...
The Manila Times6d
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 ...
MedPage Today5d
BTK Inhibitors for Follicular Lymphoma
Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...
Cure Today6d
First Patient with CD5-Positive T-Cell Lymphoma Dosed with MB-105
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
Cure Today6d
Odronextamab Elicits Responses in Some With Lymphoma Following CAR-T
Among some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, treatment with the bispecific antibody odronextamab has been associated ...
Nasdaq2d
Y-mAbs Therapeutics Initiates Phase 1 Trial of CD38-SADA Pre-targeted Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...
manilatimes6d
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
"This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” said Sarah ...